1. 64P Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases
- Author
-
UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Nassar, A.H., Zarif, T., Abou Alaiwi, S., Denu, R., Macaron, W., El-Am, E., Malvar, C., Ocejo Gallegos, J.A., Cortellini, A., Korolewicz, J.A., Sackstein, P., Aboubakar Nana, Frank, Foderaro, S., Baena Espinar, J., Woodford, R., Grynberg, S., Asnani, A., Hayek, S., Choueiri, T.K., Naqash, A-R., the ESMO Immuno-Oncology Congress 2022, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Nassar, A.H., Zarif, T., Abou Alaiwi, S., Denu, R., Macaron, W., El-Am, E., Malvar, C., Ocejo Gallegos, J.A., Cortellini, A., Korolewicz, J.A., Sackstein, P., Aboubakar Nana, Frank, Foderaro, S., Baena Espinar, J., Woodford, R., Grynberg, S., Asnani, A., Hayek, S., Choueiri, T.K., Naqash, A-R., and the ESMO Immuno-Oncology Congress 2022
- Abstract
Background : Incidence of cardiac metastasis (mets) is rising among pts with cancer. Data on the safety and clinical outcomes of ICIs on pts with cardiac mets is limited. [...]
- Published
- 2022